Ascletis Pharma Inc. has announced the initiation of a new U.S. 12-week Phase IIa clinical study involving the dosing of the first participants with obesity or overweight who have at least one weight-related comorbidity. The study is evaluating the once-monthly subcutaneous depot formulation of ASC30, a small molecule GLP-1 receptor agonist, for the treatment of obesity. The company has indicated that topline data from this study are expected to be available in the first quarter of 2026. ASC30, discovered and developed in-house by Ascletis, is designed for both oral tablet and subcutaneous injection administrations. It is protected by U.S. and global patents until 2044, without extensions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.